Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

541 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design.
Brookhart MA, Mayne TJ, Coombs C, Breskin A, Ness E, Bessonova L, Chu YJ, Li J, Fried MW, Hansen BE, Kowdley KV, Jones D, Mells G, Trivedi PJ, Hiu S, Kareithi DN, Wason J, Smith R, Seeger JD, Hirschfield GM. Brookhart MA, et al. Among authors: kowdley kv. Hepatology. 2024 Dec 2. doi: 10.1097/HEP.0000000000001174. Online ahead of print. Hepatology. 2024. PMID: 39630028
Correction to COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls.
Kowdley KV, Hirschfield GM, Coombs C, Malecha ES, Bessonova L, Li J, Rathnayaka N, Mells G, Jones DE, Trivedi PJ, Hansen BE, Smith R, Wason J, Hiu S, Kareithi DN, Mason AL, Bowlus CL, Muller K, Carbone M, Berenguer M, Milkiewicz P, Adekunle F, Villamil A. Kowdley KV, et al. Am J Gastroenterol. 2025 Jan 1;120(1):263. doi: 10.14309/ajg.0000000000003153. Epub 2024 Nov 29. Am J Gastroenterol. 2025. PMID: 39621001 No abstract available.
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis.
Roberts SB, Choi WJ, Worobetz L, Vincent C, Flemming JA, Cheung A, Qumosani K, Swain M, Grbic D, Ko HH, Peltekian KM, Abrahamyan L, Saini M, Tirona K, Aziz B, Lytvyak E, Invernizzi P, Ponsioen CY, Bruns T, Cazzagon N, Lindor K, Dalekos GN, Gatselis NK, Verhelst X, Floreani A, Corpechot C, Mayo MJ, Levy C, Londoño MC, Battezzati PM, Pares A, Nevens F, van der Meer A, Kowdley KV, Trivedi PJ, Lleo A, Thorburn D, Carbone M, Selzner N, Gulamhusein AF, Janssen H, Montano-Loza AJ, Mason AL, Hirschfield GM, Hansen BE; Canadian Network for Autoimmune Liver disease (CaNAL). Roberts SB, et al. Among authors: kowdley kv. JHEP Rep. 2024 Jul 8;6(10):101168. doi: 10.1016/j.jhepr.2024.101168. eCollection 2024 Oct. JHEP Rep. 2024. PMID: 39380718 Free PMC article.
A Rare Case of Tirzepatide-Induced Hepatotoxicity.
Sohal A, Casanova L, Kowdley KV. Sohal A, et al. Among authors: kowdley kv. ACG Case Rep J. 2024 Oct 4;11(10):e01484. doi: 10.14309/crj.0000000000001484. eCollection 2024 Oct. ACG Case Rep J. 2024. PMID: 39372916 Free PMC article.
COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls.
Kowdley KV, Hirschfield GM, Coombs C, Malecha ES, Bessonova L, Li J, Rathnayaka N, Mells G, Jones DE, Trivedi PJ, Hansen BE, Smith R, Wason J, Hiu S, Kareithi DN, Mason AL, Bowlus CL, Muller K, Carbone M, Berenguer M, Milkiewicz P, Adekunle F, Villamil A. Kowdley KV, et al. Am J Gastroenterol. 2024 Aug 14. doi: 10.14309/ajg.0000000000003029. Online ahead of print. Am J Gastroenterol. 2024. PMID: 39140490
Liver stiffness progression in biopsy-proven metabolic dysfunction-associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study.
Huang DQ, Wilson LA, Behling C, Amangurbanova M, Kleiner DE, Kowdley KV, Dasarathy S, Terrault NA, Diehl AM, Chalasani N, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J, Loomba R; NASH Clinical Research Network. Huang DQ, et al. Among authors: kowdley kv. Hepatology. 2024 Jul 19. doi: 10.1097/HEP.0000000000001015. Online ahead of print. Hepatology. 2024. PMID: 39028908
Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B Study.
Levy C, Caldwell S, Mantry P, Luketic V, Landis CS, Huang J, Mena E, Maheshwari R, Rank K, Xu J, Malkov VA, Billin AN, Liu X, Lu X, Barchuk WT, Watkins TR, Chung C, Myers RP, Kowdley KV. Levy C, et al. Among authors: kowdley kv. Clin Transl Gastroenterol. 2024 Aug 1;15(8):e00744. doi: 10.14309/ctg.0000000000000744. Clin Transl Gastroenterol. 2024. PMID: 38976363 Free PMC article. Clinical Trial.
Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis.
Hussain N, Ma C, Hirschfield G, Walmsley M, Hanford P, Vesterhus M, Kowdley K, Bergquist A, Ponsioen C, Levy C, Assis D, Schramm C, Bowlus C, Trauner M, Aiyegbusi OL, Jairath V, Trivedi PJ. Hussain N, et al. Among authors: kowdley k. BMJ Open. 2024 Jun 26;14(6):e080143. doi: 10.1136/bmjopen-2023-080143. BMJ Open. 2024. PMID: 38926149 Free PMC article.
541 results